Recently Featured

Ascendis Wins FDA Approval for Achondroplasia Drug, Waits on EU Action

March 5, 2026
The FDA on Friday granted approval to Ascendis Pharma for its once-weekly treatment, navepegritide, aimed at addressing achondroplasia, a genetic disorder resulting in dwarfism. This pivotal decision marks a significant milestone for Ascendis, positioning it within a competitive landscape that may soon feature multiple players targeting this rare condition. The approval of navepegritide not only…

Most-Favored Nation Drug Pricing Agreements Set to Expire After Three Years for Some Firms

March 5, 2026
WASHINGTON — Recent disclosures from Securities and Exchange Commission filings reveal that the “most-favored nation” drug pricing agreements established during the Trump administration will expire after three years for certain pharmaceutical companies. While these deals were touted as a means to ensure the U.S. does not overpay for prescription drugs, the specifics surrounding their implementation…

Merck Cuts More Than 150 Jobs at New Gardasil Vaccine Plant in North Carolina

March 4, 2026
Merck is cutting over 150 jobs at its recently opened Gardasil vaccine manufacturing facility in North Carolina, a significant move that underscores ongoing challenges in the biopharmaceutical sector. This decision comes less than a year after the plant’s inauguration, raising questions about the sustainability of investments in vaccine production amidst fluctuating demand and operational costs.…

CHMP Recommends Moderna’s Flu-Covid Shot and Novartis Pill for Hives

March 4, 2026
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of six new medicines, prominently featuring Moderna’s flu-Covid-19 combination vaccine and Novartis’ oral treatment for chronic hives. This recommendation is a critical step in the regulatory process, as it signals the potential for these innovative therapies to enter the…

Ongoing Cases